Patent Litigation in Singapore Pharma: Act Now or Is It Too Late?

When a competitor is preparing to enter the market with a potentially infringing product, the question is no longer whether infringement exists. In patent litigation in Singapore pharma, the real issue is whether it is still worth acting now—or whether the window to act effectively has already passed.

In Singapore, patent litigation in the pharmaceutical sector is not merely a legal step. It is a business decision that directly affects revenue, market share, and the timing of competitor entry.

A Common Challenge in Practice

Many pharmaceutical companies across Southeast Asia (including those operating in Singapore) face the same dilemma:

• Concerns over high litigation costs
• Uncertainty about the likelihood of success
• Difficulty deciding whether to act immediately or wait

As a result, decisions are often delayed.

In many cases, that delay becomes the most costly mistake.

By the time a generic product is close to launch:

• negotiating leverage has weakened
• legal options become more limited
• and market share may already begin to erode

Timing Matters More Than Winning

In Singapore, there is a critical moment that often determines the outcome:

when a generic applies for marketing approval

At that stage:

• the generic must notify the patent proprietor
• and declare that the patent is either not infringed or invalid

From that point, the patent proprietor has:

45 days to decide whether to take action

If action is taken within this window, a significant advantage becomes available:

a 30-month moratorium on product approval

This means:

• the competitor cannot enter the market for up to 30 months
• without the need to wait for a final court decision

What Should Be Considered

Before deciding, it is important to assess the commercial realities:

Time

• Litigation typically takes approximately 1.5 to 2 years
• However, the effect of the moratorium can be immediate

Cost

• Legal costs are not fully recoverable (typically around 30–40%)
• These costs should be viewed as a strategic investment, not merely an expense

Impact

• Preserves market share
• Helps maintain pricing stability
• Provides time to adjust broader business strategy

Accordingly, the more relevant question is not:

“What will the litigation cost?”

But rather:

“What is the value of the market position being protected?”

Available Options (Beyond Litigation)

In such situations, several approaches may be considered:

1. Litigation (early action)

• Appropriate where timing is critical
• Objective: prevent market entry

2. Negotiation or settlement

• Potentially faster
• Requires sufficient leverage

3. Licensing

• Enables monetisation of patent rights without prolonged dispute

4. Waiting (highest risk)

• Often chosen
• Frequently results in reduced strategic control

The Risk of Inaction

The consequences of delaying action are often underestimated:

• Competitors may enter the market earlier
• Downward pressure on pricing
• Weakened position as an innovator
• Difficulty recovering market share, even if litigation is ultimately successful

In many cases:

companies may succeed legally, but lose commercially.

When Should Action Be Taken?

Timely action is typically required in the following situations:

• When a generic submits a marketing approval application
• When there are clear indications of imminent product launch
• When the potential revenue impact is significant

At this stage:

delaying the decision often results in a loss of leverage

Why Singapore Is Different from Other SEA Markets

Singapore’s framework is relatively structured and strategy-driven:

• a patent linkage system
• a 30-month regulatory moratorium
• a clear and predictable legal process

However, this also means:

the system tends to favour parties who act early

If action is delayed, the same framework may instead facilitate faster competitor entry.

A Business Decision, Not Just a Legal One

In the context of patent litigation in Singapore’s pharmaceutical sector, the decision to act is not purely legal.

It involves:

• when to act
• whether meaningful leverage still exists
• and the extent of market position to be protected

Because in this space:

outcomes are shaped not only by who is right—but by who acts at the right time.

If you are currently:

• receiving notice from a generic applicant, or
• anticipating market entry in the near term

this is not a situation for prolonged analysis.

It is a point at which you must determine:

whether there is still time to act strategically—or whether that window is already closing.